PMID- 19544372
OWN - NLM
STAT- MEDLINE
DCOM- 20091112
LR  - 20211020
IS  - 1522-2594 (Electronic)
IS  - 0740-3194 (Print)
IS  - 0740-3194 (Linking)
VI  - 62
IP  - 3
DP  - 2009 Sep
TI  - Magnetic resonance imaging-guided adoptive cellular immunotherapy of central 
      nervous system tumors with a T1 contrast agent.
PG  - 599-606
LID - 10.1002/mrm.22030 [doi]
AB  - Dendritic cells (DCs) are the most effective antigen-presenting cells (APCs) and 
      are used in a variety of immunotherapeutic approaches. Adoptive cellular 
      immunotherapy (ACI) of cancer using DCs has attracted much interest due to their 
      capacity to promote immunity in prophylactic and therapeutic protocols. As one 
      approach, DCs are injected into patients or tumor-bearing animals, to trigger 
      specific antitumor immunity. In that framework, several approaches to DC delivery 
      have been reported, including direct intratumoral injection; this has yielded 
      positive but variable results. The underlying reasons for this have not been 
      fully determined, but major hypotheses include technical difficulties in 
      delivering cells into tumors and tumor-mediated immunosuppression. Image-guided 
      ACI offers the potential to establish that DCs are efficiently delivered to the 
      tumor site, which might eliminate some of the variability. Therefore, we 
      developed highly sensitive methods for monitoring the injection or trafficking of 
      DCs into tumors using a clinically approved formulation of a gadolinium-based 
      magnetic resonance imaging (MRI) contrast agent, Gd(III)-HP-DO3A (ProHance). We 
      determined the labeling efficiency of DCs with this formulation; that labeling 
      DCs with this agent did not inhibit expression of surface markers important for 
      antigen presentation and activation of naive T cells; that their capacity to 
      interact with natural killer (NK) cells was not reduced; and that their migration 
      was not diminished. Further, we determined that ProHance-labeled DCs can be 
      effectively imaged in vivo in established central nervous system tumors.
FAU - Sengar, Raghvendra S
AU  - Sengar RS
AD  - Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, 
      Pennsylvania, USA.
FAU - Spokauskiene, Laima
AU  - Spokauskiene L
FAU - Steed, Daniel P
AU  - Steed DP
FAU - Griffin, Patricia
AU  - Griffin P
FAU - Arbujas, Norma
AU  - Arbujas N
FAU - Chambers, William H
AU  - Chambers WH
FAU - Wiener, Erik C
AU  - Wiener EC
LA  - eng
GR  - CA098717/CA/NCI NIH HHS/United States
GR  - P30 CA047904/CA/NCI NIH HHS/United States
GR  - P41-EB001977/EB/NIBIB NIH HHS/United States
GR  - P41 EB001977/EB/NIBIB NIH HHS/United States
GR  - CA47904/CA/NCI NIH HHS/United States
GR  - P30 CA047904-21S59033/CA/NCI NIH HHS/United States
GR  - R01 CA098717/CA/NCI NIH HHS/United States
GR  - R01 CA098717-04/CA/NCI NIH HHS/United States
GR  - P41 EB001977-23/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Magn Reson Med
JT  - Magnetic resonance in medicine
JID - 8505245
RN  - 0 (Contrast Media)
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Organometallic Compounds)
RN  - 0199MV609F (gadoteridol)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/immunology/*pathology/*surgery
MH  - Cells, Cultured
MH  - Contrast Media
MH  - Dendritic Cells/immunology/*pathology/*transplantation
MH  - Gadolinium
MH  - *Heterocyclic Compounds
MH  - Image Enhancement/methods
MH  - Immunotherapy, Adoptive/*methods
MH  - Magnetic Resonance Imaging/*methods
MH  - Magnetics
MH  - Male
MH  - *Organometallic Compounds
MH  - Rats
MH  - Rats, Inbred F344
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Surgery, Computer-Assisted/methods
PMC - PMC2924576
MID - NIHMS227159
EDAT- 2009/06/23 09:00
MHDA- 2009/11/13 06:00
PMCR- 2010/08/20
CRDT- 2009/06/23 09:00
PHST- 2009/06/23 09:00 [entrez]
PHST- 2009/06/23 09:00 [pubmed]
PHST- 2009/11/13 06:00 [medline]
PHST- 2010/08/20 00:00 [pmc-release]
AID - 10.1002/mrm.22030 [doi]
PST - ppublish
SO  - Magn Reson Med. 2009 Sep;62(3):599-606. doi: 10.1002/mrm.22030.